Antitumor agent-86 (compound 5a) demonstrates efficacy against MCF-7 breast cancer cells, manifesting an inhibitory concentration (IC 50) of 2.62 µM. It promotes apoptosis and cell cycle arrest, exhibiting antineoplastic effects through the disruption of RAS/PI3K/Akt/JNK signaling pathways [1].

抗肿瘤药物Antitumor agent-86（0-200 μM；48小时）对MCF-7、MDA-MB-231、Caco-2和PANC-1癌细胞的增殖表现出剂量依赖性的抑制作用，其IC50值分别是2.617、6.778、14.8和23.58 μM [1]。同一药物在2.62 μM浓度和48小时处理下，能诱发细胞凋亡和细胞周期停滞，减少MCF-7细胞中p-RAS蛋白及PI3K和Akt的mRNA表达，降低p-JNK蛋白的水平 [1]。此外，Antitumor agent-86在相同浓度和时间条件下，能够上调p21基因的表达 [1]。